Sequence 5 from Patent US 20030077289

General Information


DCTPep ID  DCTPep01239

Peptide Name   Sequence 5 from Patent US 20030077289

Sequence  YARAAARQARA

Sequence Length  11

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic construct

Type  Synthetic peptide

Classification

  

ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available



Structure Information


PDB ID  Not available

Predicted Structure  Not available

(Please note that there is the predicted structure, predicted by AlphaFold)

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C50H85N21O14

Absent amino acids  CDEFGHIKLMNPSTVW

Theoretical pI  11.71

Acidic residues  0

Basic residues  3

Polar residues  1

Molecular weight (Average)  1204.36

Molecular weight (Monoisotopic)  1203.66

Common amino acids  A

Net charge  3

Instability index (II)  48.13

Aliphatic index  54.55

Grand average of hydropathicity (GRAVY)  -0.682

Half Life 
  2.8 hours (mammalian reticulocytes, in vitro).
  10 min (yeast, in vivo).
  2 min (Escherichia coli, in vivo).

Extinction coefficients 
  Ext. coefficient 1490
  Abs 0.1% (=1 g/l) 1.237

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2003/0077289 A1

Patent Title  Use of cell-penetrating peptides to generate antitumor immunity.

Other Iinformation  Granted Patent Family: 6s / 6ex; Family Jurisdictions: CN, WO, AU, US; Legal Status: Discontinued; Application No: 7755502; Filed:Feb 15, 2002; Published: Apr 24, 2003; Earliest Priority: Feb 15, 2001

Other Published ID  CN1309417C  CN1503628A  WO2002064057A2  WO2002064057A3 




DCTPep is developed by Dr.Zheng's team.